03/06/2023

NETRIS Pharma publishes new article "From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors" published in EMBO Molecular Medicine - March 6th, 2023

Reading : 12 min

Check out our most recent published article:

https://www.embopress.org/doi/full/10.15252/emmm.202216732

 

Suggested articles

logo Nature article
08/30/2023

NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology

* Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models. * Paired biopsies, pre-and-on NP137 treatment, highlight a statistically significant reduction of tumor epithelial-to-mesenchymal transition. * Netrin-1 blockade with NP137, is confirmed as a clinical strategy to alleviate resistance to standard treatments, in multiple clinical indications, including EC.

Reading : 15 min
Bio Boston 2023
05/16/2023

NETRIS Pharma attending the Bio International Convention in Boston (June 5-8, 2023)

NETRIS Pharma, a clinical-stage immuno-oncology pharmaceutical company pioneering NETRIN-1-based drug discovery and development, is confirming today that CEO and Founder Patrick Mehlen, and CFO Christophe Guichard, will be attending the Bio International Convention taking place June 5-8, 2023, in Boston, MS. Meet with us at the Partnering booth ! For any information, please send an email to christopheguichard@netrispharma.com

Reading : 1 min
logo1
03/29/2023

NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137

Lap-NET1 study will evaluate safety and efficacy of anti-netrin-1 antibody NP137 in combination with m_FOLFIRINOX for first line patients with Locally Advanced Pancreatic Ductal Adenocarcinoma

Reading : 5 min